
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova's sales experienced robust growth, boasting a 29% increase to $803 million in 2024, with management projecting continued growth through guidance of $940-955 million for the upcoming year. The company's focus on expanding the aura6000's market share is evident, with optimistic projections in the Bull Case scenario estimating sales of $120 million in 2027 and $280 million by 2029 as the market share grows from 9.0% to 14.9%. With significant revenue streams originating from both the US market and Europe, LivaNova's strategic positioning in cardiopulmonary solutions and neuromodulation devices suggests a strong potential for future revenue growth.
Bears say
LivaNova's financial outlook is negatively affected by anticipated revenue growth slowing to the low-single digits due to persistent challenges in its Neuromodulation and Cardiovascular sectors, coupled with operating margin contraction. The company faces significant risks, including the potential failure to secure FDA approval for the aura6000 device, which could hinder Neuromodulation and Cardiopulmonary growth and result in weaker-than-expected margin improvements. Overall, these factors contribute to a bearish scenario, with forecasts of below-consensus earnings further compounding the company's financial struggles.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares